The report provides a detailed analysis essential for establishing a Foslevodopa production plant. It encompasses all critical aspects necessary for Foslevodopa production, including the cost of Foslevodopa production, Foslevodopa plant cost, Foslevodopa production costs, and the overall Foslevodopa production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Foslevodopa production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Foslevodopa is a water-soluble prodrug used to support the treatment of Parkinson’s disease. It is utilised as a medication in combination with other medicines to help manage symptoms of Parkinson’s disease. It is designed to convert into levodopa inside the body, helping increase dopamine levels in patients who struggle with movement symptoms such as stiffness, tremors, and slow mobility.
It finds its major application in advanced treatment systems, including continuous infusion therapies that provide a steady supply of the active drug and help reduce fluctuations. It also supports better control of motor symptoms in individuals who do not respond well to standard dosing.
The demand for Foslevodopa is primarily driven by its application as a medication in advanced treatment setups for Parkinson’s disease, which promotes its market expansion. Its application as a prodrug in providing more stable levodopa levels and improving motor control in advanced Parkinson’s disease treatments also boosts its demand in the healthcare sector. Its involvement in continuous infusion systems and combination therapies, where steady and controlled delivery of levodopa is required, further contributes to its demand in the neurology and pharmaceutical sectors.
Its demand as a prodrug used to enhance long-term treatment outcomes in Parkinson’s care also fuels its market growth. The rising number of Parkinson’s cases worldwide and the increasing shift toward precision dosing and long-acting treatment systems also contribute to its market expansion.
Various factors such as the cost and availability of specialised raw materials, adherence to regulatory standards for neurological treatments, and compliance with safety and environmental requirements significantly influence industrial Foslevodopa procurement. In addition, progress in drug-delivery technology, supplier reliability, sustainability measures, and efficient supply chain operations also impact its overall market.
Raw Material for Foslevodopa Production
According to the Foslevodopa production plant project report, the major raw materials for Foslevodopa production includes 3,4-Dihydroxybenzaldehyde or Protocatechuic Aldehyde.
Production Process of Foslevodopa
The extensive Foslevodopa production cost report consists of the following industrial production process:
- Production via Chemical Synthesis: The production process of Foslevodopa starts with the preparation of a suitable aromatic aldehyde (3,4-dihydroxybenzaldehyde) that undergoes a Horner–Wadsworth–Emmons olefination to form the required α,β-unsaturated intermediate. This reaction forms the backbone needed for the amino acid portion of the molecule. Then, the intermediate is taken into an enantioselective hydrogenation step, which reduces the double bond while establishing the correct chiral centre that matches the natural configuration of levodopa. Further, the material is converted into its phosphate form through controlled phosphorylation at the 4′-position of the aromatic ring, which gives the monophosphate structure, i.e. Foslevodopa. Then, the obtained product undergoes purification and isolation to complete the process and form Foslevodopa suitable for therapeutic use as the final product.
Foslevodopa is a phosphate prodrug of levodopa and exists in the form of an odourless, white to off-white powder. It is highly soluble in water because of its phosphate group, and the IUPAC name of the compound is (2S)-2-amino-3-(3,4-dihydroxyphenyl)propyl dihydrogen phosphate. The molecular formula of the compound is C9H12NO7P, and its molar mass is 277.17 g/mol. The compound should be handled with general laboratory precautions, as pharmacologically active substances may pose risks if mishandled.